Chimeric Autoantibody Receptor (CAAR) T Cells as a Precision Therapy for Antigen-Specific B Cell Depletion in PLA2R Membranous Nephropathy: FR-OR32

摘要: Background:Primary membranous nephropathy (MN) is an autoimmune disease caused by autoantibodies against podocyte antigens, leading to glomerular damage, nephrotic syndrome, and potentially end-stage renal disease requiring dialysis or transplant. Phospholipase A2 receptor (PLA2R) autoantibodies are found in 70-80% of primary MN patients, co-localize with PLA2R and IgG4 glomerular immune deposits, and correlate with disease activity, supporting their causative role in disease pathogenesis. B cell depletion with rituximab is an effective strategy for treatment of primary MN. However, patients often require repeat treatments for disease relapse or maintenance of remission, and infectious serious adverse events are observed in up to 6.2% of rituximab-treated patients, highlighting the need for therapy that induces durable disease remission without generalized immunosuppression. Chimeric antigen …